- Home
- VRXA vs DOUG Comparison
VRXA vs DOUG Comparison
Compare VRXA & DOUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRXA | DOUG |
|---|---|---|
| Founded | 2021 | 1911 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building operators |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.4M | 134.5M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VRXA | DOUG |
|---|---|---|
| Price | $1.15 | $1.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 278.2K | ★ 579.4K |
| Earning Date | N/A | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 118.68 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $955,578,000.00 |
| Revenue This Year | N/A | $0.59 |
| Revenue Next Year | N/A | $7.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.95 | $1.38 |
| 52 Week High | $4.50 | $3.03 |
Technical Indicators
Market Signals| Indicator | VRXA | DOUG |
|---|---|---|
| Relative Strength Index (RSI) | 47.39 | 49.51 |
| Support Level | $1.04 | $1.53 |
| Resistance Level | $1.41 | $1.61 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 45.00 | 55.56 |
Price Performance
Historical ComparisonAbout VRXA Veraxa Biotech AG Ordinary Shares
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is engaged in the real estate services business and seeks to acquire or invest in additional real estate services businesses. The Company also offers, through its subsidiaries and ventures, development marketing services and ancillary services, including mortgage, title, and escrow services. It generates revenue from commissions and other brokerage income, property management, and other ancillary services.